Valion Bio, Inc.
TIVC
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$19M
▼ -57.0% YoY
Op. Margin
–
ROIC
-92.27%
▲ +60.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▼ -22.9% YoY
Op. Cash Flow (TTM)
-$15M
▼ -22.3% YoY
Net Debt
$15M
Cash & Equiv.
$2M
3Y CAGR: -14.7%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with TIVC
Valion Bio (TIVC) in three numbers
Questions about Valion Bio
Is Valion Bio a high-quality business?
Valion Bio scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at -14.7%. The Quality tab shows every check against its target.
Does Valion Bio (TIVC) pay a dividend?
No. Valion Bio (TIVC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in TIVC's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TIVC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.